DK3861985T3 - Sammensætninger og fremgangsmåder til behandling af øjensygdomme - Google Patents

Sammensætninger og fremgangsmåder til behandling af øjensygdomme Download PDF

Info

Publication number
DK3861985T3
DK3861985T3 DK21155644.4T DK21155644T DK3861985T3 DK 3861985 T3 DK3861985 T3 DK 3861985T3 DK 21155644 T DK21155644 T DK 21155644T DK 3861985 T3 DK3861985 T3 DK 3861985T3
Authority
DK
Denmark
Prior art keywords
compositions
treatment
methods
eye diseases
diseases
Prior art date
Application number
DK21155644.4T
Other languages
English (en)
Inventor
Michael Goldstein
Charles D Blizzard
Ankita Desai
Arthur Driscoll
Original Assignee
Ocular Therapeutix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/029830 external-priority patent/WO2020219892A1/en
Application filed by Ocular Therapeutix Inc filed Critical Ocular Therapeutix Inc
Application granted granted Critical
Publication of DK3861985T3 publication Critical patent/DK3861985T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2201/00—Properties
    • C08L2201/06—Biodegradable
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2312/00—Crosslinking

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DK21155644.4T 2020-02-06 2021-02-05 Sammensætninger og fremgangsmåder til behandling af øjensygdomme DK3861985T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062970828P 2020-02-06 2020-02-06
PCT/US2020/029830 WO2020219892A1 (en) 2019-04-25 2020-04-24 Hydrogel implants for lowering intraocular pressure
US202163136305P 2021-01-12 2021-01-12
US202163139123P 2021-01-19 2021-01-19

Publications (1)

Publication Number Publication Date
DK3861985T3 true DK3861985T3 (da) 2023-07-24

Family

ID=76707925

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21155644.4T DK3861985T3 (da) 2020-02-06 2021-02-05 Sammensætninger og fremgangsmåder til behandling af øjensygdomme

Country Status (16)

Country Link
US (3) US20210251893A1 (da)
EP (2) EP3861985B1 (da)
JP (2) JP7451732B2 (da)
KR (1) KR20220151622A (da)
CN (1) CN115066232A (da)
AU (1) AU2021215929A1 (da)
BR (1) BR112022015533A2 (da)
CA (1) CA3166738A1 (da)
DK (1) DK3861985T3 (da)
ES (1) ES2952213T3 (da)
FI (1) FI3861985T3 (da)
IL (1) IL295357A (da)
MX (1) MX2022009435A (da)
PT (1) PT3861985T (da)
TW (1) TW202140031A (da)
WO (1) WO2021158968A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240042713A1 (en) * 2021-12-06 2024-02-08 Ocular Therapeutix, Inc. Extruded ocular inserts or implants and methods thereof
WO2024035690A1 (en) * 2022-08-12 2024-02-15 Ocular Therapeutix, Inc. Organogels for sustained drug delivery, methods of preparation and use thereof

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993071A (en) 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US3949750A (en) 1974-10-07 1976-04-13 Freeman Jerre M Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same
US4915684A (en) 1988-06-21 1990-04-10 Mackeen Donald L Method and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus
US5469867A (en) 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
US6027470A (en) 1998-06-10 2000-02-22 Eagle Vision, Inc. Punctum plug and method for inserting the same into the punctual opening
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US7347850B2 (en) 1998-08-14 2008-03-25 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
EP1137373A4 (en) 1998-12-04 2004-05-19 Chandrashekhar P Pathak BIOCOMPATIBLE, CROSSLINKED POLYMERS
US6294679B1 (en) 1999-04-12 2001-09-25 Chirotech Technology Limited Intermediate for the synthesis of prostaglandins
US7166730B2 (en) 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
US6982090B2 (en) 2001-05-10 2006-01-03 Gillespie Donald E More easily visualized punctum plug configurations
US7109371B2 (en) 2004-01-05 2006-09-19 Johnson Matthey Public Limited Company Prostaglandin synthesis
US20050197614A1 (en) 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20080124400A1 (en) 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US8939910B2 (en) 2006-03-28 2015-01-27 Devicor Medical Products, Inc. Method for enhancing ultrasound visibility of hyperechoic materials
US8795711B2 (en) 2006-03-31 2014-08-05 Mati Therapeutics Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
US9173773B2 (en) 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
EP2066300B2 (en) 2006-09-28 2019-01-23 Novartis Ag Self-preserved aqueous pharmaceutical compositions
US20080114076A1 (en) 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
US8080593B2 (en) 2006-11-29 2011-12-20 University Of Southern California Reversible thermoresponsive adhesives for implants
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
PT3202814T (pt) 2007-02-15 2019-11-26 Tolmar Therapeutics Inc Poli-(lactido/glicolido) de libertação imediata reduzida e métodos de produção de polímeros
US8673286B2 (en) 2007-04-09 2014-03-18 Northwestern University DOPA-functionalized, branched, poly(aklylene oxide) adhesives
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
KR20100050566A (ko) 2007-09-07 2010-05-13 큐엘티 플러그 딜리버리, 인코포레이티드 눈물 임플랜트 및 이에 관련된 방법
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
AR071312A1 (es) 2008-04-09 2010-06-09 Scinopharm Taiwan Ltd Proceso para la preparacion de analogos de prostaglandina y sus intermediarios
JP2011520805A (ja) 2008-05-09 2011-07-21 キューエルティー プラグ デリバリー，インク． 緑内障および高眼圧症治療のための活性剤の持続送達
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
KR101045935B1 (ko) 2009-03-11 2011-07-01 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법
US20100247606A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
CN102596097B (zh) 2009-06-03 2015-05-20 弗赛特实验室有限责任公司 一种眼插入件
JP6087147B2 (ja) 2009-06-22 2017-03-01 ジョンソン、マッセイ、パブリック、リミテッド、カンパニーＪｏｈｎｓｏｎ Ｍａｔｔｈｅｙ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ プロスタグランジンの精製方法
WO2011008756A1 (en) 2009-07-13 2011-01-20 Irix Pharmaceuticals Synthesis of prostanoids
CA2769162C (en) 2009-07-31 2017-12-05 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
NZ599316A (en) 2009-10-16 2013-02-22 Cayman Chemical Co Inc Process for the preparation of f-series prostaglandins
CA2776723C (en) 2009-10-29 2018-09-25 Ascendis Pharma As Sterilization of biodegradable hydrogels
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
RU2565445C2 (ru) 2010-01-22 2015-10-20 Аллерган, Инк. Внутрикамерные имплантаты с пролонгированным высвобождением терапевтического агента
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
CN103917202B (zh) 2011-09-14 2016-06-29 弗赛特影像5股份有限公司 眼插入件装置和方法
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
KR20190090048A (ko) 2011-12-05 2019-07-31 인셉트, 엘엘씨 의료용 유기젤 방법 및 조성물
HU231203B1 (hu) 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
KR101861824B1 (ko) 2012-03-20 2018-05-29 삼성디스플레이 주식회사 박막 증착 장치 및 그것을 이용한 박막 증착 방법
EP2911623B1 (en) 2012-10-26 2019-08-14 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
CN104884049A (zh) 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
HU230744B1 (hu) 2012-11-30 2018-01-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
EP2964194B1 (en) 2013-03-05 2022-08-17 University of Pittsburgh - Of the Commonwealth System of Higher Education Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
CN105358146B (zh) 2013-03-08 2019-11-29 波利艾克蒂瓦有限公司 用于递送生物活性剂的聚合物缀合物
EP2981248B1 (en) 2013-04-01 2020-09-02 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
US9115109B2 (en) 2013-08-15 2015-08-25 Chirogate International Inc. Processes and intermediates for the preparations of isomer free prostaglandins
US10100028B2 (en) 2013-09-30 2018-10-16 Patheon Api Services Inc. Synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
MY177958A (en) 2013-10-31 2020-09-28 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof
CA2930390A1 (en) 2013-11-15 2015-05-21 Glaukos Corporation Ocular implants configured to store and release stable drug formulations
EP3861982A3 (en) 2013-12-06 2021-09-01 Allergan, Inc. Intracameral implant for treatment of an ocular condition
US10010610B2 (en) 2014-01-16 2018-07-03 Retinal Therapies, LLC Compositions and methods for the treatment of intraocular neovascularization and/or leakage
HU231214B1 (hu) 2014-03-13 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás nagytisztaságú prosztaglandinok előállítására
JP7092502B2 (ja) 2014-12-10 2022-06-28 インセプト・リミテッド・ライアビリティ・カンパニー ハイドロゲル薬物送達インプラント
CA2978600A1 (en) 2015-03-06 2016-09-15 Envisia Therapeutics, Inc. Implant applicators and methods of administering implants
EP4279064A3 (en) 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
WO2017015616A1 (en) 2015-07-22 2017-01-26 Envisia Therapeutics, Inc. Ocular protein delivery
JP2018525078A (ja) 2015-07-22 2018-09-06 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ 被覆された涙点プラグ
WO2017015675A1 (en) * 2015-07-23 2017-01-26 Envisia Therapeutics, Inc. Glaucoma treatment via intracameral ocular implants
US20170028078A1 (en) * 2015-07-28 2017-02-02 Layerbio, Inc. Sustained-release drug formulations for glaucoma
US10105371B2 (en) 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
JP2018536484A (ja) 2015-11-25 2018-12-13 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ 形状変化する薬物送達デバイス及び方法
EP3515406A1 (en) * 2016-09-23 2019-07-31 Incept, LLC Intracameral drug delivery depots
JP7407595B2 (ja) 2016-10-05 2024-01-04 タイタン ファーマシューティカルズ インコーポレイテッド バースト放出を低減する薬剤送達用の埋込可能な装置
GB201622024D0 (en) 2016-11-14 2017-02-08 Inventage Lab Inc Apparatus and method for large scale production of monodisperse, microsheric and biodegradable polymer-based drug delivery
KR102142026B1 (ko) 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
JP7278223B2 (ja) 2017-06-13 2023-05-19 アイポイント ファーマシューティカルズ，インコーポレイティド 生体浸食性薬物送達デバイス
MX2020000377A (es) 2017-07-11 2020-07-14 Sustained Nano Systems Llc Esterilizacion mediante radiacion de formas de dosis de polimero hipercomprimido.
CN111050754A (zh) 2017-07-17 2020-04-21 商福溪生技有限公司 用于递送活性剂的微粒制剂
US20190192341A1 (en) * 2017-11-09 2019-06-27 Allergan, Inc. Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect
WO2019126172A1 (en) 2017-12-19 2019-06-27 University Of Tennessee Research Foundation W/o/w microemulsions for ocular administration
EP3920988A4 (en) 2019-02-06 2022-11-02 Tearclear Corp. SYSTEMS AND METHODS FOR REMOVAL OF PRESERVATIVES FROM OPHTHALMIC FORMULATIONS INCLUDING COMPLEXING AGENTS
US20200306182A1 (en) 2019-03-05 2020-10-01 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
US20200337990A1 (en) 2019-04-25 2020-10-29 Ocular Therapeutix, Inc. Hydrogel implants for lowering intraocular pressure
TWI826685B (zh) 2019-05-02 2023-12-21 瑞士商愛爾康公司 可溶解聚合物眼睛插入物及其使用方法
JP2021147330A (ja) 2020-03-16 2021-09-27 株式会社リコー 徐放性粒子及びその製造方法
US11285109B2 (en) 2020-05-08 2022-03-29 M. Technique Co., Ltd. Microsphere comprising PLGA or PLA in which a biologically active substance is uniformly dispersed and a sustained release formulation comprising the same

Also Published As

Publication number Publication date
MX2022009435A (es) 2022-08-25
EP3861985B1 (en) 2023-06-14
US20210251893A1 (en) 2021-08-19
AU2021215929A1 (en) 2022-08-04
FI3861985T3 (fi) 2023-08-07
EP3861985A1 (en) 2021-08-11
IL295357A (en) 2022-10-01
US20230285281A1 (en) 2023-09-14
TW202140031A (zh) 2021-11-01
CN115066232A (zh) 2022-09-16
JP7451732B2 (ja) 2024-03-18
ES2952213T3 (es) 2023-10-30
KR20220151622A (ko) 2022-11-15
EP4252776A2 (en) 2023-10-04
WO2021158968A1 (en) 2021-08-12
JP2023512715A (ja) 2023-03-28
US11622935B2 (en) 2023-04-11
EP4252776A3 (en) 2023-11-22
BR112022015533A2 (pt) 2022-09-27
JP2024063192A (ja) 2024-05-10
US20220218643A1 (en) 2022-07-14
CA3166738A1 (en) 2021-08-12
PT3861985T (pt) 2023-08-03

Similar Documents

Publication Publication Date Title
DK3717471T3 (da) Nye forbindelser og lægemiddelsammensætninger heraf til behandling af sygdomme
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
DK3673080T3 (da) Antisense-oligomerer til behandling af lidelser og sygdomme
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
DK3442580T3 (da) Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
DK3858977T3 (da) Stamme til forebyggelse og behandling af stofskiftesygdomme, og brugen heraf
DK3341001T3 (da) Sammensætning og fremgangsmåde til behandling og profylakse af tarminfektion og -inflammation
DK3600270T3 (da) Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
DK3902803T3 (da) Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
DK3405215T3 (da) Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3866772T3 (da) 2,3,5-trimethyl-6-nonylcyclohexa-2,5-dien-1,4-dion til undertrykkelse og behandling af alpha-synucleinopathier, tauopathier og andre lidelser
CA188123S (fr) Paire de boucles d'oreilles
IL287802A (en) Preparations and methods for the treatment of eye diseases
IL287796A (en) Preparations and methods for the treatment of diseases mediated by ATPase
DK3744316T3 (da) Oftalmisk farmaceutisk sammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK3861985T3 (da) Sammensætninger og fremgangsmåder til behandling af øjensygdomme
EP3713553A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF EYE DISEASES
IL290891A (en) Preparations and methods for the treatment of vascular diseases
DK3445362T3 (da) Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
DK3774897T3 (da) Fremgangsmåder og systemer til udvælgelse og behandling af patienter med inflammatoriske sygdomme
DK3660545T3 (da) Silikonehydrogelsammensætning, silikonehydrogellinse og fremgangsmåde til fremstilling af silikonehydrogellinse
DK3743064T3 (da) Behandling af proteinuri